Intercontinental Exchange, (NYSE:ICE) [Trend Analysis] retains strong position in active trade, as shares scoring 0.21% to $58.49 in a active trade session, while looking at the shares volume, around 214407 shares have changed hands in this session. The New York Stock Exchange or NYSE, part of Intercontinental Exchange (ICE), said that it has entered into contract to acquire the National Stock Exchange, Inc or NSX. Terms were not disclosed and the financial impact will not be material to ICE.
The transaction is expected to close in the first quarter of 2017, subject to customary regulatory approvals.As a result, subject to Securities and Exchange Commission (SEC) approval, NSX will continue to operate as a licensed National Market System (NMS) exchange, and no longer has plans to cease trading on December 16 as it previously reported.
The acquisition will also give the NYSE Group an additional U.S. exchange license, bringing its total to four. NSX will be distinct from NYSE’s three listings exchanges – NYSE, NYSE MKT and NYSE Arca Equities – which have unique market models designed for corporate and ETP issuers. The firm has institutional ownership of 93.50%, while insider ownership included 0.40%. ICE attains analyst recommendation of 2.10 with week’s performance of -0.92%. Investors looking further ahead will note that the Price to next year’s EPS is 11.84%.
Vericel Corporation (NASDAQ:VCEL) [Trend Analysis] knocking active thrust in leading trading session, shares a loss of -3.66% to 3.95 with around 1.68 Million shares have changed hands in this session. Vericel Corp. (VCEL) declared that its treatment for cartilage defects of the knee was authorized by the Food and Drug Administration. Volume topped 2.3 million shares ahead of the open, making the stock the most actively traded in the premarket.
Vericel said MACI is the first FDA-authorized cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. “We believe that the introduction of MACI, along with investments to expand our commercial organization and implement new patient support programs, positions Vericel to generate important growth in 2017 and beyond,” said Chief Executive Nick Colangelo. The stock is going forward its fifty-two week low with 121.59% and lagging behind from its 52-week high price with -41.70%.
Similar, the positive performance for the quarter recorded as 71.55% and for the year was 125.27%, while the YTD performance remained at 58.91%. VCEL has Average True Range for 14 days of 0.31.